Patent · US Active

Muteins with tear lipocalin having affinity to human c-met receptor tyrosine kinase and methods for obtaining the same

US9751920B2 · kind B2 · utility

0Cited by

0References

2Claims

0Family size

Assignee

Pieris Pharmaceuticals GmbH · DE

Inventors

Gabriele Matschiner · Munich, DE
Andreas Hohlbaum · Paunzhausen, DE
Martin Huelsmeyer · Freising, DE
Stefan Trentmann · Freising, DE

Key dates

Filing date	Dec 14, 2015
Grant date	Sep 5, 2017
Priority date	—
Expiry date	Dec 14, 2035

Classification

Technology area (CPC G)Physics
CPC primaryG01N2333/91205
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to novel muteins derived from human tear lipocalin having affinity to human c-Met receptor tyrosin kinase (c-Met). The invention also refers to a corresponding nucleic acid molecule encoding such a mutein and to a method for its generation. The invention further refers to a method for producing such a mutein. Finally, the invention is directed to a pharmaceutical composition comprising such a lipocalin mutein as well as to various uses of the mutein.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.